Rockwell Medical (NASDAQ:RMTI) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rockwell Medical (NASDAQ:RMTI - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, StockNews.com upgraded Rockwell Medical from a sell rating to a hold rating in a research report on Wednesday, June 19th.

Rockwell Medical Price Performance

NASDAQ:RMTI traded up $0.31 during mid-day trading on Wednesday, hitting $4.10. 1,993,561 shares of the company's stock traded hands, compared to its average volume of 255,449. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 2.00. The company has a market cap of $124.30 million, a PE ratio of -11.61 and a beta of 1.47. The firm's 50 day simple moving average is $2.36 and its 200 day simple moving average is $1.90. Rockwell Medical has a 1 year low of $1.16 and a 1 year high of $4.38.

Rockwell Medical (NASDAQ:RMTI - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $23.01 million. Rockwell Medical had a negative return on equity of 6.96% and a negative net margin of 5.06%. During the same quarter in the prior year, the company earned ($0.18) EPS. Sell-side analysts expect that Rockwell Medical will post -0.03 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Armistice Capital LLC lifted its holdings in shares of Rockwell Medical by 22.5% during the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company's stock worth $5,670,000 after acquiring an additional 592,000 shares during the period. Renaissance Technologies LLC increased its position in Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company's stock worth $181,000 after purchasing an additional 92,189 shares during the last quarter. Vanguard Group Inc. raised its stake in Rockwell Medical by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company's stock worth $1,856,000 after purchasing an additional 43,302 shares during the period. Finally, SkyOak Wealth LLC boosted its holdings in shares of Rockwell Medical by 47.3% in the 1st quarter. SkyOak Wealth LLC now owns 25,110 shares of the company's stock valued at $42,000 after purchasing an additional 8,065 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.